VP301 Treatment for Multiple Myeloma, Lymphoma and Solid Tumors

Unknown Phase 1 NCT05698888

Study Description

This study will evaluate the safety and pharmacokinetics of VP301 in patients who have relapsed or refractory multiple myeloma, lymphoma, or solid tumors. The study will consist of two parts: dose escalation and dose expansion. Dose escalation will evaluate the increasing doses of VP301 to determine the maximum tolerated dose or recommended Phase 2 dose. Dose expansion will enroll patients with relapsed myeloma and lymphoma and treat them with VP301 at the MTD or RP2D. This study aims to test the safety and tolerability of VP301 in treating these conditions.

Study Details

Registry ID:
NCT05698888
Conditions:
Solid Tumors, Adult, Multiple Myeloma, Lymphoma
Phase:
Phase 1
Target Enrollment:
2 participants
Start Date:
Age Range:
18–999 years
Healthy Volunteers:
No

Study Locations (1 site)

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →